Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




May
22
Today In Oncology
Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status
Guideline-Concordant Care Is Associated With Improved Survival. So, Why Aren’t More AYA Patients Receiving This Care?
FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer
Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma
AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo